Alligator Bioscience (ATORX) Q3 2026 earnings summary

Executive summary

• Refocused operations on HLX22 financial interests, with no development costs borne for the programme; Henlius is advancing it in global Phase III.

• Independent mitazalimab development was discontinued; operations are being wound down while out-licensing or divestment of mitazalimab and other assets is pursued.

• The rights issue raised SEK 58.8m before costs to support the wind-down and smaller organisation, but not the wait until potential HLX22 royalties.

Financial highlights

• Q3 net sales were SEK 0.2m vs SEK 0.5m YoY; operating loss was SEK 19.3m vs SEK 17.3m, and net loss SEK 16.7m vs SEK 12.3m.

• 9M net sales were SEK 0.2m vs SEK 0.5m; operating loss was SEK 73.2m vs SEK 83.3m, and net loss SEK 53.1m vs SEK 22.3m.

• Q3 cash flow was SEK 24.6m vs an outflow of SEK 8.8m; quarter-end cash and cash equivalents were SEK 41.3m vs SEK 25.1m YoY.

• Q3 R&D costs were SEK 14.2m, including SEK 10.3m for mitazalimab, driven by committed study-material production and OPTIMIZE-1 costs; trailing Phase III preparation costs also kept operating costs elevated.

Outlook and guidance

• HLX22 Phase III topline data are estimated in H2 2027; potential launch is estimated in H2 2029, with first royalty revenues expected from 2030.

• Estimated effective royalty is up to 1.75% of HLX22 net sales; estimated annual peak royalty income is SEK 150m–450m, not a forecast.

• Reduced cost base is expected to be fully in effect from Q2 2027, with minimal-organization costs targeted at ~SEK 1m per month.

• CEO transition is planned for 1 January 2027, when CFO Johan Giléus will combine the CEO and CFO roles; TO 15 and TO 16 warrants are exercisable in January 2027 and January 2028, respectively.